

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	22	2,4,5-trimethylthiazole	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/11/09 21:24

10/036,856

FILE 'MEDLINE' ENTERED AT 21:14:51 ON 09 NOV 2004

FILE 'HCAPLUS' ENTERED AT 21:14:51 ON 09 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 21:14:51 ON 09 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 21:14:51 ON 09 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> d his

(FILE 'HOME' ENTERED AT 21:03:46 ON 09 NOV 2004)

FILE 'REGISTRY' ENTERED AT 21:03:53 ON 09 NOV 2004
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 21:04:24 ON 09 NOV 2004

FILE 'REGISTRY' ENTERED AT 21:06:10 ON 09 NOV 2004
L3 STRUCTURE UPLOADED
L4 2 S L3 SSS SAM
L5 83 S L3 SSS FULL

→ deleted species

FILE 'STNGUIDE' ENTERED AT 21:07:53 ON 09 NOV 2004

FILE 'MEDLINE, HCAPLUS, BIOSIS, EMBASE' ENTERED AT 21:09:05 ON 09 NOV 2004
L6 191 S L5

FILE 'STNGUIDE' ENTERED AT 21:09:22 ON 09 NOV 2004

FILE 'MEDLINE, HCAPLUS, BIOSIS, EMBASE' ENTERED AT 21:14:51 ON 09 NOV 2004

=> s l6 and (?glaucom? or ocular? or ophthalmol? or intra(2a)ocular? or
intraocular? or retinopath? or diabet? or eye?)

L7 2 L6 AND (?GLAUCOM? OR OCULAR? OR OPHTHALMOL? OR INTRA(2A) OCULAR
? OR INTRAOCULAR? OR RETINOPATH? OR DIABET? OR EYE?)

=> dup rem l7


PROCESSING COMPLETED FOR L7

L8 2 DUP REM L7 (0 DUPLICATES REMOVED)

=> d l8 abs cbib kwic hitstr 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
GI

DELACROIX



AB Provided, among things, is a method of treating or ameliorating an indication of the invention in an animal, including a human, comprising administering an effective amount of a compound of formula I, wherein: W and Y are independently N or, resp., CRW or CRY; Z is O, S or NRZ; Q is -CH₂- or -(CO)-CH₂-, where the methylene is bounded to a ring nitrogen; RW and RY are independently hydrogen, alkyl, -C.tplbond.CRE, -CH₂-C.tplbond.CRP, aryl, alkylamino, arylamino, C(O)NH₃, S(O)₂NH₂, etc.; RZ is alkyl, -C.tplbond.CRE, -CH₂-C.tplbond.CRP, aryl, arylalkyl, or aroylalkyl; R1 and R2 are independently hydrogen, alkyl or hydroxymethyl; R3 is H or -CH₃; R4 is acetamido, hydrogen, Me, amino, -C.tplbond.CRE, -CH₂-C.tplbond.CRP, alkylthio, fluoromethyl, etc.; X- is a pharmaceutically acceptable anion.

2002:927189 Document Number 138:11441 Method for treating fibrotic diseases or other indications. Gall, Martin (Alteon, Inc., USA). PCT Int. Appl. WO 2002096362 A2 20021205, 37 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US16846 20020530. PRIORITY: US 2001-PV294438 20010530.

IT **Eye, disease**
(**retinopathy**; method for treating fibrotic diseases or other indications)

IT 477252-66-7P **477252-67-8P** 477252-68-9P **477252-69-0P**
477252-70-3P 477252-71-4P 477252-72-5P 477252-73-6P 477252-74-7P
477252-75-8P 477252-76-9P 477252-77-0P **477252-78-1P**
477252-79-2P **477252-80-5P** 477252-81-6P 477252-82-7P
477252-83-8P 477252-84-9P 477252-85-0P 477252-86-1P 477252-87-2DP,
derivs.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treating fibrotic diseases or other indications)

IT **477252-67-8P 477252-69-0P 477252-78-1P**
477252-80-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treating fibrotic diseases or other indications)

RN 477252-67-8 HCAPLUS


CN Thiazolium, 3-[2-(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)-2-oxoethyl]-2,4,5-trimethyl- (9CI) (CA INDEX NAME)

10/036,856




RN 477252-69-0 HCAPLUS

CN Thiazolium, 3-[2-(3,4-dihydro-6-hydroxy-2,5,8-trimethyl-2H-1-benzopyran-2-yl)-2-oxoethyl]-2,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 477252-78-1 HCAPLUS

CN Thiazolium, 3-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl]-2,4,5-trimethyl- (9CI) (CA INDEX NAME)





RN 477252-80-5 HCAPLUS

CN Thiazolium, 3-[(3,4-dihydro-6-hydroxy-2,5,8-trimethyl-2H-1-benzopyran-2-yl)methyl]-2,4,5-trimethyl- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
GI

DELACROIX



- AB Provided is a method of decreasing **intraocular** pressure or improving **ocular** accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH₂Cl₂, EDCI, HOBt, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).
- 2002:521496 Document Number 137:93744 Preparation of thiazole derivatives for the treatment of fibrotic diseases. Wagle, Dilip; Martin, Gail; Bell, Stanely C.; Lavoie, Edmond J. (Alteon, Inc., USA). PCT Int. Appl. WO 2002053161 A1 20020711, 56 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US50822 20011228. PRIORITY: US 2000-PV259107 20001229; US 2001-PV259239 20010102; US 2001-PV296247 20010606.
- AB Provided is a method of decreasing **intraocular** pressure or improving **ocular** accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; . . .
- IT 288-47-1P, Thiazole 13623-11-5P, 2,4,5-Trimethylthiazole 18640-74-9P, 2-Isobutylthiazole 19952-47-7P, 2-Amino-4-chlorobenzothiazole 109317-64-8P 181070-25-7P, 2,6-Diaminobenzothiazole dihydrochloride 289491-05-0P 302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide 441285-73-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug; preparation of thiazole derivs. for treatment of fibrotic diseases)
- IT 13623-11-5P, 2,4,5-Trimethylthiazole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug; preparation of thiazole derivs. for treatment of fibrotic diseases)
- RN 13623-11-5 HCAPLUS
 CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)

10/036,856




10/036,856

=> d 19 1

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 13623-11-5 REGISTRY
CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2,4,5-trimethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,4,5-Trimethylthiazole
CN NSC 170614
CN Trimethylthiazole
FS 3D CONCORD
MF C6 H9 N S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSChem, IFICDB, IFIPAT,
IFIUDB, MEDLINE, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA Caplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses); NORL (No role in record)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent); USES (Uses); NORL (No role in record)

selected species



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

151 REFERENCES IN FILE CA (1907 TO DATE)
151 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

10/036,856

FILE 'REGISTRY' ENTERED AT 21:19:43 ON 09 NOV 2004

E 2,4,5-TRIMETHYL THIAZOLE/CN

E 2,4,5-TRIMETHYLTHIAZOLE/CN

L9

1 S E3



FILE 'STNGUIDE' ENTERED AT 21:20:30 ON 09 NOV 2004

FILE 'MEDLINE, HCAPLUS, BIOSIS, EMBASE' ENTERED AT 21:20:50 ON 09 NOV 2004

=> s l9 and (?glaucom? or ocular? or ophthalmol? or intra(2a)ocular? or
intraocular? or retinopath? or diabet? or eye?)

L10 1 L9 AND (?GLAUCOM? OR OCULAR? OR OPHTHALMOL? OR INTRA(2A) OCULAR
? OR INTRAOCULAR? OR RETINOPATH? OR DIABET? OR EYE?)

=> d 110 abs cbib kwic 1

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
GI

AB Provided is a method of decreasing **intraocular** pressure or improving **ocular** accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH₂Cl₂, EDCI, HOBT, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).

2002:521496 Document Number 137:93744 Preparation of thiazole derivatives for the treatment of fibrotic diseases. Wagle, Dilip; Martin, Gail; Bell, Stanely C.; Lavoie, Edmond J. (Alteon, Inc., USA). PCT Int. Appl. WO 2002053161 A1 20020711, 56 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US50822 20011228. PRIORITY: US 2000-PV259107 20001229; US 2001-PV259239 20010102; US 2001-PV296247 20010606.

AB Provided is a method of decreasing **intraocular** pressure or improving **ocular** accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; . . .

IT 288-47-1P, Thiazole 13623-11-5P, 2,4,5-Trimethylthiazole 18640-74-9P, 2-Isobutylthiazole 19952-47-7P, 2-Amino-4-chlorobenzothiazole 109317-64-8P 181070-25-7P, 2,6-Diaminobenzothiazole dihydrochloride 289491-05-0P 302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide 441285-73-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of thiazole derivs. for treatment of fibrotic diseases)

=>

10/036,856